TY - JOUR
T1 - Transscleral cyclophotocoagulation in the treatment of glaucoma
T2 - patient selection and perspectives
AU - Liebenthal, Rebecca
AU - Schuman, Joel S.
N1 - Funding Information:
The authors have received an unrestricted grant from Research to Prevent Blindness (New York, NY).
Funding Information:
JS Schuman declares the following: Consultant/Advisor, Equity Owner for Aerie Pharmaceuticals, Inc; Grant Support from BrightFocus Foundation; Consultant/Advisor for Boehringer Ingelheim; Patents/Royalty/Consultant/Advisor Carl Zeiss Meditec; Grant Support from National Eye Institute; Equity Owner, Patents/Royalty for Ocugenix; Consultant/Advisor, Equity Owner for Ocular Therapeutix, Inc.; Consultant/Advisor, Equity Owner for Opticient; Consultant/Advisor for Perfuse, Inc.; Consultant/Advisor for Regeneron, Inc.; Consultant/Advisor for SLACK Incorporated; Intellectual property for New York University, Massachusetts Eye and Ear Infirmary and Massachusetts Institute of Technology, Tufts University, and University of Pittsburgh. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.
Publisher Copyright:
© 2021 Informa UK Limited, trading as Taylor & Francis Group.
PY - 2021
Y1 - 2021
N2 - Introduction Cyclodestructive procedures involve destroying part of the ciliary epithelium to reduce production of aqueous humor and lower intraocular pressure (IOP). Due to its complication rate, cycloablation was historically reserved for eyes with refractory glaucoma that have failed previous filtration procedures, have poor vision and IOP control despite maximal medical therapy, and for relief of pain in blind eyes. Areas covered In this review paper, we cover different forms of transscleral cyclophotocoagulation (TCPC), their degrees of success, and their complication rates. Contact diode laser transscleral cyclophotocoagulation is currently a commonly used method. Micropulse diode laser transscleral cyclophotocoagulation is a newer paradigm that has shown promising results. We also review the outcomes of TCPC in eyes with different subtypes of glaucoma and ocular history. As the modalities improve, TCPC may be safer than previously assumed, and the indications for TCPC may be expanded. Expert opinion In general, TCPC is an effective and relatively safe way to treat patients with glaucoma. More comparative studies are required to determine if TCPC should be used at earlier stages of disease.
AB - Introduction Cyclodestructive procedures involve destroying part of the ciliary epithelium to reduce production of aqueous humor and lower intraocular pressure (IOP). Due to its complication rate, cycloablation was historically reserved for eyes with refractory glaucoma that have failed previous filtration procedures, have poor vision and IOP control despite maximal medical therapy, and for relief of pain in blind eyes. Areas covered In this review paper, we cover different forms of transscleral cyclophotocoagulation (TCPC), their degrees of success, and their complication rates. Contact diode laser transscleral cyclophotocoagulation is currently a commonly used method. Micropulse diode laser transscleral cyclophotocoagulation is a newer paradigm that has shown promising results. We also review the outcomes of TCPC in eyes with different subtypes of glaucoma and ocular history. As the modalities improve, TCPC may be safer than previously assumed, and the indications for TCPC may be expanded. Expert opinion In general, TCPC is an effective and relatively safe way to treat patients with glaucoma. More comparative studies are required to determine if TCPC should be used at earlier stages of disease.
KW - Glaucoma
KW - Nd:YAG laser
KW - Neovascular glaucoma
KW - cyclodestruction
KW - diode laser
KW - micropulse transscleral cyclophotocoagulation
KW - primary open-angle glaucoma
KW - pseudoexfoliation glaucoma
KW - transscleral cyclophotocoagulation
UR - http://www.scopus.com/inward/record.url?scp=85111139158&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85111139158&partnerID=8YFLogxK
U2 - 10.1080/17469899.2021.1951232
DO - 10.1080/17469899.2021.1951232
M3 - Review article
AN - SCOPUS:85111139158
SN - 1746-9899
VL - 16
SP - 357
EP - 375
JO - Expert Review of Ophthalmology
JF - Expert Review of Ophthalmology
IS - 5
ER -